Sunitha V Bachawal1, Jae Mo Park1,2, Keerthi S Valluru1, Mathias Dyrberg Loft1, Stephen A Felt3, José G Vilches-Moure3, Yamil F Saenz3, Bruce Daniel1, Andrei Iagaru1, Geoffrey Sonn1,4, Zhen Cheng1, Daniel M Spielman1, Jürgen K Willmann5,6. 1. Department of Radiology, Stanford University, Stanford, CA, USA. 2. Advanced Imaging Research Center, University of Texas Southwestern Medical Center, Dallas, TX, USA. 3. Department of Comparative Medicine, Stanford University, Stanford, CA, USA. 4. Department of Urology, Stanford University, Stanford, CA, USA. 5. Department of Radiology, Stanford University, Stanford, CA, USA. willmann@stanford.edu. 6. Department of Radiology, Molecular Imaging Program at Stanford, School of Medicine, Stanford University, 300 Pasteur Drive, Room H1307, Stanford, CA, 94305-5621, USA. willmann@stanford.edu.
Abstract
PURPOSE: To assess whether simultaneous hyperpolarized C-13 magnetic resonance spectroscopy (MRS)/positron emission tomography (PET)/multiparametric magnetic resonance (mpMR) imaging is feasible in an orthotopic canine prostate cancer (PCa) model using a clinical PET/MR system and whether the combined imaging datasets can be fused with transrectal ultrasound (TRUS) in real time for multimodal image fusion-guided targeted biopsy of PCa. PROCEDURES: Institutional Animal Care and Use Committee approval was obtained for this study. Canine prostate adenocarcinoma (Ace-1) cells were orthotopically injected into the prostate of four dogs. Once tumor engraftment was confirmed by TRUS, simultaneous hyperpolarized C-13 MRS of [1-13C]pyruvate, PET (2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG), [68Ga]NODAGA-SCH1), and mpMR (T2W, DWI) imaging was performed using a clinical PET/MR system. Multimodality imaging data sets were then fused with TRUS and image-guided targeted biopsy was performed. Imaging results were then correlated with histological findings. RESULTS: Successful tumor engraftment was histologically confirmed in three of the four dogs (dogs 2, 3, and 4) and simultaneous C-13 MRS/PET/mpMR was feasible in all three. In dog 2, C-13 MRS showed increased lactate signal in the tumor (lactate/totalC = 0.47) whereas mpMR did not show any signal changes. In dog 3, [18F]FDG-PET (SUVmean = 1.90) and C-13 MRS (lactate/totalC = 0.59) showed elevated metabolic activity in the tumor. In dog 4, [18F]FDG (SUVmean = 2.43), [68Ga]NODAGA-SCH1 (SUVmean = 0.75), and C-13 MRS (Lac/totalC = 0.53) showed elevated uptake in tumor compared to control tissue and multimodal image fusion-guided biopsy of the tumor was successfully performed. CONCLUSION: Simultaneous C-13 MRS/PET/mpMR imaging and multimodal image fusion-guided biopsy is feasible in a canine PCa model.
PURPOSE: To assess whether simultaneous hyperpolarized C-13 magnetic resonance spectroscopy (MRS)/positron emission tomography (PET)/multiparametric magnetic resonance (mpMR) imaging is feasible in an orthotopic canine prostate cancer (PCa) model using a clinical PET/MR system and whether the combined imaging datasets can be fused with transrectal ultrasound (TRUS) in real time for multimodal image fusion-guided targeted biopsy of PCa. PROCEDURES: Institutional Animal Care and Use Committee approval was obtained for this study. Canine prostate adenocarcinoma (Ace-1) cells were orthotopically injected into the prostate of four dogs. Once tumor engraftment was confirmed by TRUS, simultaneous hyperpolarized C-13 MRS of [1-13C]pyruvate, PET (2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG), [68Ga]NODAGA-SCH1), and mpMR (T2W, DWI) imaging was performed using a clinical PET/MR system. Multimodality imaging data sets were then fused with TRUS and image-guided targeted biopsy was performed. Imaging results were then correlated with histological findings. RESULTS: Successful tumor engraftment was histologically confirmed in three of the four dogs (dogs 2, 3, and 4) and simultaneous C-13 MRS/PET/mpMR was feasible in all three. In dog 2, C-13 MRS showed increased lactate signal in the tumor (lactate/totalC = 0.47) whereas mpMR did not show any signal changes. In dog 3, [18F]FDG-PET (SUVmean = 1.90) and C-13 MRS (lactate/totalC = 0.59) showed elevated metabolic activity in the tumor. In dog 4, [18F]FDG (SUVmean = 2.43), [68Ga]NODAGA-SCH1 (SUVmean = 0.75), and C-13 MRS (Lac/totalC = 0.53) showed elevated uptake in tumor compared to control tissue and multimodal image fusion-guided biopsy of the tumor was successfully performed. CONCLUSION: Simultaneous C-13 MRS/PET/mpMR imaging and multimodal image fusion-guided biopsy is feasible in a canine PCa model.
Authors: Stacy Loeb; Marc A Bjurlin; Joseph Nicholson; Teuvo L Tammela; David F Penson; H Ballentine Carter; Peter Carroll; Ruth Etzioni Journal: Eur Urol Date: 2014-01-09 Impact factor: 20.096
Authors: Jill M Keller; George R Schade; Kimberly Ives; Xu Cheng; Thomas J Rosol; Morand Piert; Javed Siddiqui; William W Roberts; Evan T Keller Journal: Prostate Date: 2013-01-17 Impact factor: 4.104
Authors: Sarah J Nelson; John Kurhanewicz; Daniel B Vigneron; Peder E Z Larson; Andrea L Harzstark; Marcus Ferrone; Mark van Criekinge; Jose W Chang; Robert Bok; Ilwoo Park; Galen Reed; Lucas Carvajal; Eric J Small; Pamela Munster; Vivian K Weinberg; Jan Henrik Ardenkjaer-Larsen; Albert P Chen; Ralph E Hurd; Liv-Ingrid Odegardstuen; Fraser J Robb; James Tropp; Jonathan A Murray Journal: Sci Transl Med Date: 2013-08-14 Impact factor: 17.956
Authors: Andreas Clemmensen; Adam E Hansen; Pernille Holst; Christina Schøier; Sissel Bisgaard; Helle H Johannesen; Jan Henrik Ardenkjær-Larsen; Annemarie T Kristensen; Andreas Kjaer Journal: Eur J Nucl Med Mol Imaging Date: 2020-07-03 Impact factor: 9.236